Last week, the RBDCOV Project Consortium gathered for its annual onsite meeting at the historic Palau Macaya in Barcelona.
This year’s discussions revolved around key achievements during the project’s final period, with a special focus on enhancing its visibility within the scientific community.
Key takeaways from the meeting:
- Clinical trials showcased promising safety and immunogenicity profiles in both adults with immunocompromising conditions and pediatric populations.
- The project continues to prioritize inclusivity in clinical trials, addressing ethical and technical challenges to ensure diverse representation and equitable healthcare solutions.
At Asphalion, we are proud to serve as the Regulatory Partner for this innovative initiative, guiding every step to ensure its success.
For more information, reach out to us at [email protected] or explore the latest project updates here: https://rbdcov.eu/
Let’s continue driving progress in science and healthcare!
For further information, contact us at: [email protected]
